Entrectinib (RXDX-101)

目录号:S7998 别名: NMS-E628 中文名称:恩曲替尼

仅限科研使用

Entrectinib (RXDX-101, NMS-E628) 是一种口服生物可利用的泛-TrkA/B/CROS1ALK 抑制剂,IC50范围为 0.1~1.7 nM。Entrectinib (RXDX-101) 可诱导自噬。Phase 2。

Entrectinib (RXDX-101) Chemical Structure

CAS: 1108743-60-7

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1556.1 现货
RMB 875.36 现货
RMB 3073.41 现货
RMB 6935.43 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Entrectinib (RXDX-101)发表文献28篇:

产品安全说明书

Trk receptor抑制剂选择性比较

生物活性

产品描述 Entrectinib (RXDX-101, NMS-E628) 是一种口服生物可利用的泛-TrkA/B/CROS1ALK 抑制剂,IC50范围为 0.1~1.7 nM。Entrectinib (RXDX-101) 可诱导自噬。Phase 2。
靶点
TrkA [1] TrkB [1] TrkC [1] ROS1 [1] ALK [1]
体外研究

Entrectinib selectively blocks proliferation of ALK-dependent cell lines and potently inhibits ALK‐dependent signaling. Entrectinib also highly inhibits cell growth of the NSCLC cell line NCI‐H2228 bearing the EML4-ALK rearrangement. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NITNPXNHfW6ldHnvckBie3OjeR?= MXW3NkBpenN? NViyW5BTUW6qaXLpeIlwdiCxZjDoeY1idiCWRVygLFM{PiC{ZYPp[JVmeyliZoXz[YQuXFKNQjCoOFU2KHSxIEiyNkBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWeubzDhd5NigSxiSVO1NEA:KDBwMECzJO69VS5? M3Tzc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MECzO|YyLz5{N{CwN|c3OTxxYU6=
BAF3 Ml2zSpVv[3Srb36gZZN{[Xl? MYW3NkBpenN? NYHzfG5OUW6qaXLpeIlwdiCxZjDoeY1idiCWRVygLFM{PiC{ZYPp[JVmeyliZoXz[YQuXFKNQTCoOFQxKHSxIEe5OkBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWeubzDhd5NigSxiSVO1NEA:KDBwMECzJO69VS5? NYf6[nRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNFM4PjFpPkK3NFA{PzZzPD;hQi=>
BAF3 MUPGeY5kfGmxbjDhd5NigQ>? NUXNUo1qPzJiaILz MXHJcohq[mm2aX;uJI9nKGi3bXHuJHRGVCBqM{O2JJJme2mmdXXzLUBnfXOnZD3UVmtEKCh2NUSgeI8hQDJ3IILld4llfWW|KTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRWY{KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwhfGm2ZYKt[4xwKGG|c3H5MEBKSzVyIE2gNE4xODNizszNMi=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
BAF3 NXnwd|ZnTnWwY4Tpc44h[XO|YYm= MY[3NkBpenN? MWLJcohq[mm2aX;uJI9nKGi3bXHuJHRGVCBqM{O2JJJme2mmdXXzLUBnfXOnZD3SU3MyKChzOEmxJJRwKDJ|NEegdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgZ4VtdCC2aYTldk1odG9iYYPzZZktKEmFNUCgQUAxNjByNTFOwG0v M1;nR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MECzO|YyLz5{N{CwN|c3OTxxYU6=
KM12 NVXhOpprSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGHmS|k4OiCqcoO= NVjmR4JuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLUVEzKGOnbHzzJIV5eHKnc4PpcochXFKNQTDwdo91\WmwIHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDJR|UxKD1iMD6wNVch|ryPLh?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
SU-DHL1 MX3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NE\nZ3E4OiCqcoO= M{n5PGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNOSClZXzsd{BmgHC{ZYPzbY5oKEGOSzDwdo91\WmwIHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDJR|UxKD1iMD6wNlQh|ryPLh?= M1\qd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MECzO|YyLz5{N{CwN|c3OTxxYU6=
BAF3 MY\GeY5kfGmxbjDhd5NigQ>? NEfTeGE4OiCqcoO= NXiwNpRQUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC2DTFugLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCjc4PhfUwhUUN3MDC9JFAvODJ6IN88UU4> NGnnb209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CwN|c3OSd-MkewNFM4PjF:L3G+
KARPAS299 NXHF[|BpSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NVPYS2hCPzJiaILz M1q5dGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JINmdGxidHn0[ZIu\2yxIHHzd4F6NCCLQ{WwJF0hOC5yM{Gg{txONg>? NVnRVWVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNFM4PjFpPkK3NFA{PzZzPD;hQi=>
SUP-M2 NGC4eVFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MoXtO|IhcHK| M1;tdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XQMW0zKGOnbHzzJIV5eHKnc4PpcochSUyNIIDyc5RmcW5iaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIFnDOVAhRSByLkC0NUDPxE1w MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
BAF3 M32xdGZ2dmO2aX;uJIF{e2G7 M2HFZlczKGi{cx?= M2PaOGlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiTEGxPVZOKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIu\2yxIHHzd4F6NCCLQ{WwJF0hOC5yNkeg{txONg>? M4m1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MECzO|YyLz5{N{CwN|c3OTxxYU6=
NCI-H2228 MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3Kwd|czKGi{cx?= Mk[2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMh\XiycnXzd4lv\yCDTFugdJJwfGWrbjDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygTWM2OCB;IECuNFY5KM7:TT6= MoPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
MV411 NGCyRmlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX[3NkBpenN? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YNEGxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDJR|UxKD1iMD6wPFEh|ryPLh?= NF3VXnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CwN|c3OSd-MkewNFM4PjF:L3G+
SR786 NV\BTll3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGX1OIc4OiCqcoO= MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOUN{i2JINmdGy|IHX4dJJme3OrbnegRWxMKHC{b4TlbY4hcW6ldXLheIVlKG[xcjC3NkBpenNiYomgZ4VtdCC2aYTldk1odG9iYYPzZZktKEmFNUCgQUAxNjB6MTFOwG0v MmfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
BAF3 M2fOSGZ2dmO2aX;uJIF{e2G7 NHWwfnc4OiCqcoO= MmrjTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCJMUKwNnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgZ4VtdCC2aYTldk1odG9iYYPzZZktKEmFNUCgQUAxNjh7NzFOwG0v MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
BA/F3 NXjB[IdZS3m2b4TvfIlkcXS7IHHzd4F6 MVO3NkBpenN? Ml;YR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTWwuOyCmZYDlcoRmdnRiQlGvSlMh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliY3XscEB1cXSncj3ncI8h[XO|YYmsJGlEPTBiPTCyMlExPCEQvF2u M1nVS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MECzO|YyLz5{N{CwN|c3OTxxYU6=
KM12 NVfu[ZhPTnWwY4Tpc44h[XO|YYm= MWmyJIhzew>? NGLrSXpKdmirYnn0bY9vKG:oIGTQUVMuXFKNQTDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iS12xNkBk\WyuczDheEBtd3diY3;uZ4VvfHKjdHnvckBi\nSncjCyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NUP3bmhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNFM4PjFpPkK3NFA{PzZzPD;hQi=>
KM12 M2[1[GZ2dmO2aX;uJIF{e2G7 NVLQO|JJOiCqcoO= MYLJcohq[mm2aX;uJI9nKFSSTUOtWHJMSSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hU01zMjDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCPQWDLJJBpd3OyaH;yfYxifGmxbjDheEBtd3diY3;uZ4VvfHKjdHnvckBi\nSncjCyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
KM12 M4PYSmZ2dmO2aX;uJIF{e2G7 NVPFdW1ROiCqcoO= Mkf5TY5pcWKrdHnvckBw\iCWUF2zMXRTU0FicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEuPMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFzD[4FudWFzIIDoc5NxcG:{eXzheIlwdiCjdDDsc5ch[2:wY3XueJJifGmxbjDh[pRmeiB{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MmfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
KM12 MVfGeY5kfGmxbjDhd5NigQ>? NVHTR41iOiCqcoO= MXrJcohq[mm2aX;uJI9nKFSSTUOtWHJMSSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hU01zMjDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIHH0JIxwfyClb37j[Y51emG2aX;uJIFnfGW{IEKgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
KM12 Mmf5SpVv[3Srb36gZZN{[Xl? NFLLUnMzKGi{cx?= NIHDeJNKdmirYnn0bY9vKG:oIGTQUVMuXFKNQTDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iS12xNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDTOkBxcG:|cHjvdplt[XSrb36gZZQhdG:5IHPvcoNmdnS{YYTpc44h[W[2ZYKgNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NYPyOHliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNFM4PjFpPkK3NFA{PzZzPD;hQi=>
KARPAS299 NVHoVXd{TnWwY4Tpc44h[XO|YYm= NG[zUFg3OCCvZz;r[y=> NUW1bnR2OTJiaILz NEjYUXBGgCC4aY\vJIlvcGmkaYTpc44hd2ZiTmDNMWFNUyCyaH;zdIhwenmuYYTpc44hcW5iU1PJSEBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKEuDUmDBV|I6QSClZXzsd{BifCB4MDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGG|IIPpcodt\SCmb4PlJI1m[XO3cnXkJIFnfGW{IEGyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
KARPAS299 NWnFOXVYTnWwY4Tpc44h[XO|YYm= NGHEXo03OCCvZz;r[y=> NHmxWGgyQCCqcoO= MlzBSZghfmm4bzDpcohq[mm2aX;uJI9nKE6STT3BUGsheGixc4Doc5J6dGG2aX;uJIlvKFOFSVSgcY92e2VieHXuc4dz[W[2ZXSge4l1cCCqdX3hckBMSVKSQWOyPVkh[2WubIOgZZQhPjBibXevb4ctKHCxIHHkcYlvcXO2ZYLl[EBieyC|aX7ncIUh\G:|ZTDt[YF{fXKnZDDh[pRmeiBzODDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NX;xXIZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNFM4PjFpPkK3NFA{PzZzPD;hQi=>
KARPAS299 M1HuVWZ2dmO2aX;uJIF{e2G7 NEDWd2o3OCCvZz;r[y=> NXzvenM1OTJiaILz Mn:5SZghfmm4bzDpcohq[mm2aX;uJI9nKE6STT3BUGsheGixc4Doc5J6dGG2aX;uJIlvKFOFSVSgcY92e2VieHXuc4dz[W[2ZXSge4l1cCCqdX3hckBMSVKSQWOyPVkh[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IE[wJI1oN2upLDDwc{Bi\G2rbnnzeIVz\WRiYYOgd4lv\2ynIHTvd4UhdWWjc4Xy[YQh[W[2ZYKgNVIhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
KARPAS299 MVLGeY5kfGmxbjDhd5NigQ>? MlrBOlAhdWdxa3e= Mkf3NVghcHK| MWXJckB3cX[xIHnubIljcXSrb36gc4YhVlCPLVHMT{BxcG:|cHjvdplt[XSrb36gbY4hW0OLRDDtc5V{\SC6ZX7v[5Ji\nSnZDD3bZRpKGi3bXHuJGtCWlCDU{K5PUBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiNkCgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCjczDzbY5odGViZH;z[UBu\WG|dYLl[EBi\nSncjCxPEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NUfiOmIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNFM4PjFpPkK3NFA{PzZzPD;hQi=>
NCI-H2228 M4XLdGFvfGm2dX3vdkBie3OjeR?= NHrYPYs{OCC2bzC2NEBu\y:tZx?= M4HRUlExKGSjeYO= NXnIfmNsSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh{MkK4JINmdGy|IIjlco9oemGodHXkJIlvKGG2aIntbYMhdnVxboWgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgN|AhfG9iNkCgcYcwc2duIIDvJIJq\CCjZH3pcol{fGW{ZXSg[o9zKDFyIHThfZM> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
NCI-H2228 NELKNFFHfW6ldHnvckBie3OjeR?= NXeyXmgyPjBibXevb4c> MmDXNVIhcHK| NFrYN4lGgCC4aY\vJIlvcGmkaYTpc44hd2ZiRV3MOE1CVEticHjvd5Bpd3K7bHH0bY9vKGmwIHH0bJlucWNiboWvcpUhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiCQQ1mtTFIzOjhiY3XscJMh[XRiNkCgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCjczDzbY5odGViZH;z[UBu\WG|dYLl[EBi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NIDtfXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CwN|c3OSd-MkewNFM4PjF:L3G+
NCI-H2228 NX31PZdKTnWwY4Tpc44h[XO|YYm= MlG1OlAhdWdxa3e= MknMNVghcHK| NIjuUY1GgCC4aY\vJIlvcGmkaYTpc44hd2ZiRV3MOE1CVEticHjvd5Bpd3K7bHH0bY9vKGmwIHH0bJlucWNiboWvcpUhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiCQQ1mtTFIzOjhiY3XscJMh[XRiNkCgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCjczDzbY5odGViZH;z[UBu\WG|dYLl[EBi\nSncjCxPEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzByM{e2NUc,OjdyMEO3OlE9N2F-
NCI-H2228 NVPoU5BpTnWwY4Tpc44h[XO|YYm= NWmyUHdTPjBibXevb4c> M4rzbVEzKGi{cx?= Mlr4SZghfmm4bzDpcohq[mm2aX;uJI9nKEWPTEStRWxMKHCqb4PwbI9zgWyjdHnvckBqdiCjdHj5cYlkKG63L371JI1wfXOnIIjlco9oemGodHXkJJdqfGhiaIXtZY4hVkOLLViyNlI5KGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiNkCgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCjczDzbY5odGViZH;z[UBu\WG|dYLl[EBi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MmfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
NCI-H2228 NVPHXFRsTnWwY4Tpc44h[XO|YYm= NXLqN41RPjBibXevb4c> NGjid2EyQCCqcoO= MXnFfEB3cX[xIHnubIljcXSrb36gc4YhTU2OND3BUGsheGixc4Doc5J6dGG2aX;uJIlvKGG2aIntbYMhdnVxboWgcY92e2VieHXuc4dz[W[2ZXSge4l1cCCqdX3hckBPS0lvSEKyNlgh[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gRWtVKHCqb4PwbI9zgWyjdHnvckBifCB4MDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGG|IIPpcodt\SCmb4PlJI1m[XO3cnXkJIFnfGW{IEG4JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NF75T4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CwN|c3OSd-MkewNFM4PjF:L3G+
KARPAS299 MWDBcpRqfHWvb4KgZZN{[Xl? NVW0N|FEOzBidH:gOlAhdWdxa3e= MYixNEBl[Xm| NF;PeFJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCzNEB1dyB4MDDt[{9s\yxicH:gZollKGGmbXnubZN1\XKnZDDmc5IhOTBiZHH5dy=> Ml[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
KARPAS299 NF62SIRCdnSrdIXtc5Ih[XO|YYm= NH\oTG4{OCC2bzC2NEBu\y:tZx?= Mn\1NVAh\GG7cx?= M3;ERWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyC6ZX7v[5Ji\nSnZDDpckBUS0mGIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKG[{ZXWgZ5Vz\WRibX;1d4Uh[XRiM{CgeI8hPjBibXevb4ctKHCxIHLp[EBi\G2rbnnzeIVz\WRiZn;yJFExKGSjeYOgcYVie3W{ZXSgc44h\GG7IEmw M4DoOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MECzO|YyLz5{N{CwN|c3OTxxYU6=
KARPAS299 MnrQSpVv[3Srb36gZZN{[Xl? NWDBRZIxOiCqcoO= MUfJcohq[mm2aX;uJI9nKE6STT;BUGsh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[XRidnXyfUBtd3diY3;uZ4VvfHKjdHnvckBi\nSncjCyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMEO3OlEoRjJ5MECzO|YyRC:jPh?=
NCI-H2228 MlvXSpVv[3Srb36gZZN{[Xl? M4PBT|IhcHK| M4O0N2lvcGmkaYTpc44hd2ZiTmDNM2FNUyCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCjdDD2[ZJ6KGyxdzDjc45k\W62cnH0bY9vKGGodHXyJFIhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NIfFemo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CwN|c3OSd-MkewNFM4PjF:L3G+
Assay
Methods Test Index PMID
Western blot Cyclin A1 / Cyclin E1 / p27 / p21 p-ALK / ALK / p-ERK / ERK / p-STAT3 / STAT3 pTrkA-Y490 / TrkA / p-PLCγ-Y783 / PLCγ pAKT / AKT 26735175 28903424 26172300
Growth inhibition assay Cell viability 26172300
体内研究 In mice bearing Karpas-299 and SR-786 xenografts, Entrectinib (p.o.) induces complete tumor regression. In NPM-ALK transgenic mice, Entrectinib induces complete regression of tumor masses observed in the thymus and in lymph nodes. [2] In the NB xenograft model, Entrectinib cotreatment enhanced the efficacy of conventional chemotherapy. [3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 560.64
化学式

C31H34F2N6O2

CAS号 1108743-60-7
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04551495 Recruiting Drug: Entrectinib|Drug: Letrozole|Drug: Goserelin Invasive Lobular Breast Carcinoma|ER+ Breast Cancer|HER2-negative Breast Cancer Jules Bordet Institute|Hoffmann-La Roche January 14 2021 Phase 2
NCT04226833 Completed Drug: entrectinib Hepatic Insufficiency Hoffmann-La Roche February 11 2020 Phase 1
NCT03796013 Completed Drug: Entrectinib Form A|Drug: Entrectinib Form C Healthy Volunteers Genentech Inc. January 10 2019 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们